SequelSEC

ANAVEX LIFE SCIENCES CORP. AVXL

Biological Products, (No Diagnostic Substances) · CIK 0001314052 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
$6.74M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$708.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-03-31
Float per share$7.92Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity7.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-03-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-09-30 — the year that filing covered.

ANAVEX LIFE SCIENCES CORP. (AVXL) reported net income of $7.82M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ANAVEX LIFE SCIENCES CORP.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

ANAVEX LIFE SCIENCES CORP. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$6.74M-$6.48M-$6.78M-$10.84M-$14.46M-$12.51M-$13.59M-$14.27M-$14.60M-$12.62M
Net income$7.82M-$5.34M-$5.68M-$9.83M-$13.24M-$11.20M-$12.11M-$11.62M-$12.21M-$10.55M
Research & developmentUnavailable$4.19M$4.66M$7.29M$9.96M$9.89M$10.45M$11.61M$11.81M$9.73M
Weighted-average diluted sharesUnavailableshares 92.68Mshares 89.03MUnavailableUnavailableshares 85.07Mshares 84.81MUnavailableshares 84.54Mshares 82.46M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$11.74M-$12.28M-$10.44M
Income tax expense$0$0$18.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.08$-0.06$-0.06Unavailable$-0.16$-0.13$-0.14Unavailable$-0.14$-0.13
Selling, general & administrative$2.03M$2.29M$2.13M$3.55M$4.50M$2.62M$3.15MUnavailableUnavailableUnavailable
General & administrativeUnavailable$2.29M$2.13M$3.55M$4.50M$2.62M$3.15M$2.66M$2.79M$2.90M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ANAVEX LIFE SCIENCES CORP. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$118.33M$127.42M$131.75M$102.58M$101.16M$115.77M$120.78M$132.19M$138.76M$139.39M
Total assets$120.14M$128.77M$132.99M$103.82M$102.43M$117.14M$124.04M$135.57M$141.54M$144.52M
Current assetsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total liabilities$7.69M$7.06M$6.37M$8.95M$11.47M$17.38M$13.13M$15.30M$11.75M$9.56M
Current liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total equity incl. NCI$112.45M$121.71M$126.62M$94.87M$90.96M$99.76M$110.92M$120.26M$129.78M$134.96M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.66M$2.52M$2.64M$4.25M$6.74M$7.00M$4.57M$9.63M$3.50M$3.73M

Cash flow

ANAVEX LIFE SCIENCES CORP. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$9.10M-$4.44M-$7.15M-$8.60M-$12.46M-$5.86M-$12.12M-$6.66M-$5.18M-$11.66M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$0$113.00K$36.32M$10.02M-$2.14M$852.00K$708.00K$89.00K$4.55M$7.28M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation-$17.08M$314.00K$1.11M$3.72M$4.32M$1.45M$2.06M$2.01M$2.49M$2.65M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ANAVEX LIFE SCIENCES CORP. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AVXL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-28View SEC filing
10-K/A · Filed 2026-08-28View SEC filing
10-Q · Filed 2026-08-28View SEC filing
10-Q · Filed 2026-02-09View SEC filing
10-K · Filed 2025-11-25View SEC filing
10-Q · Filed 2025-08-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.